Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shanghai National Clinical Research Center for Endocrine and Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai National Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, China.
Diabetes Obes Metab. 2024 Jun;26(6):2176-2187. doi: 10.1111/dom.15525. Epub 2024 Feb 28.
To assess the excess risk of cardiovascular disease (CVD) associated with different criteria for metabolic health, and the interplay of body size, insulin sensitivity and metabolic health with CVD risk.
We conducted a prospective study involving 115 638 participants from the China Cardiometabolic Disease and Cancer Cohort (4C) Study. Metabolic health was defined using three different definitions: (1) insulin sensitivity defined by homeostatic model assessment of insulin resistance index; (2) absence of metabolic syndrome according to the National Cholesterol Education Program Adult Treatment Panel III criteria; and (3) simultaneous absence of metabolic abnormalities (diabetes, hypertension, dyslipidaemia). The primary endpoint was a composite of incident CVD events comprising the first occurrence of myocardial infarction, stroke, heart failure, or cardiovascular death.
During a mean 3.61-year follow-up period, obese individuals with insulin sensitivity (multivariable-adjusted hazard ratio [HR] 1.69, 95% confidence interval [CI] 1.37-2.08), or without metabolic syndrome (HR 1.46, 95% CI 1.13-1.89) still exhibited increased CVD risks, when compared to their normal-weight counterparts. Otherwise, those with obesity but simultaneous absence of metabolic abnormalities demonstrated similar CVD risk compared to normal-weight individuals (HR 0.91, 95% CI 0.53-1.59). CVD risk increased with the number of abnormalities across body mass index categories, regardless of insulin sensitivity.
This study emphasizes the need for refined definitions of metabolic health and advocates for meticulous screening for metabolic abnormalities to reduce cardiovascular risks, even in individuals with normal weight and insulin sensitivity.
评估不同代谢健康标准与心血管疾病(CVD)风险相关的超额风险,以及身体大小、胰岛素敏感性和代谢健康与 CVD 风险之间的相互作用。
我们进行了一项前瞻性研究,涉及来自中国心血管代谢疾病和癌症队列研究(4C 研究)的 115638 名参与者。代谢健康使用三种不同的定义来定义:(1)用稳态模型评估的胰岛素抵抗指数定义的胰岛素敏感性;(2)根据国家胆固醇教育计划成人治疗小组 III 标准无代谢综合征;(3)同时无代谢异常(糖尿病、高血压、血脂异常)。主要终点是包括心肌梗死、中风、心力衰竭或心血管死亡的首发事件在内的复合 CVD 事件。
在平均 3.61 年的随访期间,与正常体重的人相比,具有胰岛素敏感性(多变量调整后的危险比[HR]1.69,95%置信区间[CI]1.37-2.08)或无代谢综合征(HR 1.46,95%CI 1.13-1.89)的肥胖个体仍表现出增加的 CVD 风险。否则,与正常体重的人相比,具有肥胖但同时无代谢异常的个体表现出相似的 CVD 风险(HR 0.91,95%CI 0.53-1.59)。无论胰岛素敏感性如何,随着 BMI 类别中异常数量的增加,CVD 风险都会增加。
这项研究强调需要对代谢健康进行更精细的定义,并主张对代谢异常进行细致的筛查,以降低心血管风险,即使在胰岛素敏感性正常的个体中也是如此。